title: Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.
abstract: Short-term intensive insulin therapy is unique amongst therapies for type 2 diabetes because it offers the potential to preserve and improve beta-cell function without additional pharmacological treatment. On the basis of clinical experience and the promising results of a series of studies in newly diagnosed patients, mostly in Asian populations, an expert workshop was convened to assess the available evidence and the potential application of short-term intensive insulin therapy should it be advocated for inclusion in clinical practice. Participants included primary care physicians and endocrinologists. We endorse the concept of short-term intensive insulin therapy as an option for some patients with type 2 diabetes at the time of diagnosis and have identified the following six areas where additional knowledge could help clarify optimal use in clinical practice: (1) generalizability to primary care, (2) target population and biomarkers, (3) follow-up treatment, (4) education of patients and providers, (5) relevance of ethnicity, and (6) health economics.
authors.affiliation: Guangdong Provincial Key Laboratory of Diabetology, Sun Yat-sen University of Medical Sciences, Canton, China.|Department of Endocrinology at Third Affiliated Hospital, Sun Yat-sen University of Medical Sciences, Canton, China.
authors.forename: Jianping
authors.initials: J
authors.lastname: Weng
authors.affiliation: Leadership Sinai Centre for Diabetes and Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
authors.forename: Ravi
authors.initials: R
authors.lastname: Retnakaran
authors.affiliation: Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Ammini
authors.initials: A
authors.lastname: Ariachery C
authors.affiliation: Department of Endocrinology, Peking University Hospital, Beijing, China.
authors.forename: Linong
authors.initials: L
authors.lastname: Ji
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Luigi
authors.initials: L
authors.lastname: Meneghini
authors.affiliation: Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
authors.forename: Wenying
authors.initials: W
authors.lastname: Yang
authors.affiliation: Department of Endocrinology and Metabolism, School of Medicine, Kyung Hee University, Seoul, South Korea.
authors.forename: Jeong-Taek
authors.initials: JT
authors.lastname: Woo
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D003226:Congresses as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D042241:Early Diagnosis; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D017410:Practice Guidelines as Topic; D012074:Remission Induction
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D007328:Insulin
keywords: consensus; short-term intensive insulin therapy; type 2 diabetes